ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140,is a first-in class “immune tolerance restorer” for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases that share the same mechanism of action.
Company Details
- Employees
- 6
- Founded
- 2001
- Address
- 50 Broadway, London,england Sw1h 0rg,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immupharma.com
- Keywords
- Autoimmune diseases, Peptides, Oncology.
- HQ
- London, England
Immupharma Plc Questions
Immupharma Plc's website is immupharma.com
Immupharma Plc's LinkedIn profile is https://uk.linkedin.com/company/immupharma-plc-imm-
Immupharma Plc has
6 employees.
View email and phone details for 6
employees at Immupharma Plc.
Immupharma Plc's industry is
Biotechnology Research
Immupharma Plc's top competitors are
Immupharma Plc,
Beacon Therapeutics,
Stealth Biotherapeutics,
Hox Therapeutics Ltd,
Redx Pharma,
Oxeltis,
Tiziana Life Sciences,
Dyodelta Biosciences Ltd.,
Neurentis Plc,
Solvias.
Immupharma Plc's categories are Biotechnology Research
Immupharma Plc's founding year is 2001
